Furthermore, Fas inhibitor treatment also downregulates the inflammatory phenotype associated with disease progression, including reduced microglia/macrophage activation and recruitment and decreased inflammatory gene expression, including the complement genes [5,18,21,22] ONL1204 has been shown to be safe in a Phase 1 clinical trial in retinal detachment (NCT03780972) and recently completed a Phase 2 clinical trial (NCT05730218) in that indication. The gene discussed is FAS; the disease is retinal detachment.